A translational research company based in Dortmund and Planegg
LDC was established in Dortmund in 2008 by the technology transfer organization Max Planck Innovation GmbH on behalf of the Max Planck Society e.V. LDC’s focus in Dortmund is on small molecule drug discovery. In 2017, a branch for the development of therapeutic antibodies was opened in Planegg, Munich. The LDC sustains a long-term partnership with the Max-Planck Society and the KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I).